Clinical and Epidemiologic Characteristics and Therapeutic Management of Patients with Vibrio Infections, Bay of Biscay, France, 2001-2019.

Bay of Biscay France Vibrio infections amputation antibacterial agents antimicrobial resistance bacteria bacterial infections death diagnosis therapeutics

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
12 2022
Historique:
entrez: 23 11 2022
pubmed: 24 11 2022
medline: 26 11 2022
Statut: ppublish

Résumé

Noncholera vibriosis is a rare, opportunistic bacterial infection caused by Vibrio spp. other than V. cholerae O1/O139 and diagnosed mainly during the hot summer months in patients after seaside activities. Detailed knowledge of circulating pathogenic strains and heterogeneities in infection outcomes and disease dynamics may help in patient management. We conducted a multicenter case-series study documenting Vibrio infections in 67 patients from 8 hospitals in the Bay of Biscay, France, over a 19-year period. Infections were mainly caused by V. alginolyticus (34%), V. parahaemolyticus (30%), non-O1/O139 V. cholerae (15%), and V. vulnificus (10%). Drug-susceptibility testing revealed intermediate and resistant strains to penicillins and first-generation cephalosporins. The acute infections (e.g., those involving digestive disorder, cellulitis, osteitis, pneumonia, and endocarditis) led to a life-threatening event (septic shock), amputation, or death in 36% of patients. Physicians may need to add vibriosis to their list of infections to assess in patients with associated risk factors.

Identifiants

pubmed: 36418019
doi: 10.3201/eid2812.220748
pmc: PMC9707594
doi:

Substances chimiques

Penicillins 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Clin Infect Dis. 2003 Jul 15;37(2):272-80
pubmed: 12856219
Emerg Infect Dis. 2016 Jul;22(7):1216-20
pubmed: 27314874
Clin Infect Dis. 2006 May 1;42(9):1298-304
pubmed: 16586390
Epidemiol Infect. 2017 May;145(7):1491-1499
pubmed: 28202099
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):E5062-71
pubmed: 27503882
Clin Microbiol Rev. 1994 Oct;7(4):419-25
pubmed: 7834599
Lancet Infect Dis. 2004 Apr;4(4):201-12
pubmed: 15050937
Epidemiol Infect. 2011 Apr;139(4):591-8
pubmed: 20546636
Emerg Infect Dis. 2011 Jan;17(1):7-15
pubmed: 21192848
Nat Rev Dis Primers. 2018 Jul 12;4(1):8
pubmed: 30002421
Clin Infect Dis. 2008 Apr 1;46(7):970-6
pubmed: 18444811
Environ Microbiol Rep. 2010 Feb;2(1):7-18
pubmed: 23765993
Springerplus. 2015 Oct 05;4:575
pubmed: 26543710
Clin Infect Dis. 2012 Jun;54 Suppl 5:S391-5
pubmed: 22572659
Clin Microbiol Rev. 2010 Apr;23(2):399-411
pubmed: 20375359
Infect Immun. 2009 May;77(5):1723-33
pubmed: 19255188
Trends Microbiol. 2017 Jan;25(1):76-84
pubmed: 27843109
Foodborne Pathog Dis. 2015 Nov;12(11):881-6
pubmed: 26287765
BMC Infect Dis. 2015 Jun 11;15:226
pubmed: 26062903
Microb Ecol. 2013 May;65(4):817-25
pubmed: 23280498
Euro Surveill. 2016 Apr 14;21(15):
pubmed: 27104237

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH